Literature DB >> 16817915

Effect of naproxen on gastric acid secretion and gastric pH.

S Rodriguez-Stanley1, N Redinger, P B Miner.   

Abstract

BACKGROUND: The mechanisms for the non-steroidal anti-inflammatory drug-induced inflammation in the stomach are unclear. AIMS: To determine if naproxen (Naprosyn, Roche, Nutley, NJ, USA) alters basal acid output, pentagastrin-stimulated maximal acid output, or fasting gastrin.
METHODS: Basal acid output and maximal acid output gastric aspirations were performed pre-naproxen and 7 days post-naproxen 500 mg b.d. in 24 healthy subjects. Volume, pH and acid mEq were determined. Fasting gastrin was obtained. Comparisons were made using paired t-tests (alpha = 0.05).
RESULTS: Dosing with naproxen did not statistically decrease mean pH of the basal acid output gastric fluid (3.3 vs. 3.1; N.S.) or the pentagastrin-stimulated maximal acid output gastric fluid (2.7 vs. 2.6; N.S.). Basal acid output total volume was significantly decreased post-naproxen (84 vs. 61 mL/h; P = 0.01), with no change in maximal acid output total volume (196 vs. 188 mL/h; N.S.). Basal acid output mean gastric acidity was significantly increased post-naproxen (0.04 vs. 0.05 mEq/mL; P = 0.03), with no change in maximal acid output mean gastric acidity after naproxen (0.10 vs. 0.10; N.S.). Gastrin was not altered by dosing with naproxen.
CONCLUSIONS: Naproxen does not influence total acid secreted but does decrease basal gastric fluid volume, thereby increasing basal gastric acid concentration. These observations define one mechanism by which non-steroidal anti-inflammatory drugs may induce gastric injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817915     DOI: 10.1111/j.1365-2036.2006.02897.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  MAGL inhibition modulates gastric secretion and motility following NSAID exposure in mice.

Authors:  Molly S Crowe; Steven G Kinsey
Journal:  Eur J Pharmacol       Date:  2017-05-03       Impact factor: 4.432

Review 2.  Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients.

Authors:  Corrado Blandizzi; Marco Tuccori; Rocchina Colucci; Giovanni Gori; Matteo Fornai; Luca Antonioli; Narcisa Ghisu; Mario Del Tacca
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease.

Authors:  David N Roberts; Philip B Miner
Journal:  Drug Healthc Patient Saf       Date:  2011-03-03

4.  Study of Melatonin as Preventive Agent of Gastrointestinal Damage Induced by Sodium Diclofenac.

Authors:  Aroha B Sánchez; Beatriz Clares; María J Rodríguez-Lagunas; María J Fábrega; Ana C Calpena
Journal:  Cells       Date:  2020-01-10       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.